|
See related Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose) inj[科基 血凝素第八因子 (重組體) 凍晶注射劑] information |
|
|
|
製造商 |
Bayer Schering Pharma |
|
代理/經銷商 |
Bayer Schering Pharma |
|
成份 |
Antihemophilic factor VIII (recombinant) |
|
適應症 |
Treatment of hemophilia A. |
|
用量 |
The dosage necessary to achieve hemostasis depends upon the type & severity of the bleeding episode, according to the following general guidelines: Minor hemorrhage Dosage necessary to maintain the therapeutic plasma level 10-20 iu/kg. Repeat dose if evidence of further bleeding. Moderate to major hemorrhage 15-30 iu/kg. Repeat one dose at 12-24 hr if needed. Major to life-threatening hemorrhage Initial dose 40-50 iu/kg. Repeat dose 20-25 iu/kg every 8-12 hr. Major surgical procedures Preoperative dose 50 iu/kg. Verify-100% activity prior to surgery. Repeat as necessary after 6-12 hr initially, & for 10-14 days until healing is complete. Prophylaxis AHF concentrates may also be administered on a regular schedule for prophylaxis of bleeding, as reported by Nilsson et al.10. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Known intolerance or allergic reaction to constituents of the preparation. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate FS. |
|
警告 |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose)[科基 血凝素第八因子 (重組體)] detailed prescribing infomation |
|
注意事項 |
click to view Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose)[科基 血凝素第八因子 (重組體)] detailed prescribing infomation |
|
不良反應 |
Burning, pruritus, erythema, dizziness, nausea, chest discomfort, sore throat, cold feet, unusual taste in the mouth, slight decrease in BP.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose)[科基 血凝素第八因子 (重組體)] detailed prescribing infomation |
|
儲存 |
View Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose)[科基 血凝素第八因子 (重組體)] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose)[科基 血凝素第八因子 (重組體)] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose)[科基 血凝素第八因子 (重組體)] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose) 凍晶注射劑 |
|
Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose) 250 IU x 1's |
|
Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose) 500 IU x 1's |
|
Kogenate FS, Antihemophilic Factor (Recombinant Formulated with Sucrose) 1000 IU x 1's |
|
|
|
Manufacturer: |
Bayer Schering Pharma |
|
Distributor: |
Bayer Schering Pharma
|
|
|
|
